Article
Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma.
Cancer discovery - 1 Mar 2022
Wu Meng-Ju, Shi Lei, Dubrot Juan, Merritt Joshua, Vijay Vindhya, Wei Ting-Yu, Kessler Emily, Olander Kira E, Adil Ramzi, Pankaj Amaya, Tummala Krishna Seshu, Weeresekara Vajira, Zhen Yuanli, Wu Qibiao, Luo Meiqi, Shen William, García-Beccaria María, Fernández-Vaquero Mirian, Hudson Christine, Ronseaux Sebastien, Sun Yi, Saad-Berreta Rodrigo, Jenkins Russell W, Wang Tong, Heikenwälder Mathias, Ferrone Cristina R, Goyal Lipika, Nicolay Brandon, Deshpande Vikram, Kohli Rahul M, Zheng Hongwu, Manguso Robert T, Bardeesy Nabeel
Abstract excerpt
Isocitrate dehydrogenase 1 mutations (mIDH1) are common in cholangiocarcinoma. (R)-2-hydroxyglutarate generated by the mIDH1 enzyme inhibits multiple α-ketoglutarate-dependent enzymes, altering epigenetics and metabolism. Here, by developing mIDH1-driven genetically engineered mouse models, we show that mIDH1 supports cholangiocarcinoma tumor maintenance through an immunoevasion program centered on dual...
Topics
Join the communities discussing this publication.